Drug development for neglected diseases: a deficient market and a public-health policy failure
暂无分享,去创建一个
Els Torreele | James Orbinski | N. Ford | P. Olliaro | Nathan Ford | Piero Olliaro | E. Torreele | R. Laing | Richard Laing | Patrice Trouiller | J. Orbinski | P. Trouiller
[1] Anthony S. Fauci,et al. The AIDS research model: implications for other infectious diseases of global health importance. , 2001, JAMA.
[2] Carlos Maria Correa,et al. Intellectual Property Rights, the WTO and Developing Countries: The TRIPS Agreement and Policy Options , 2000 .
[3] E. M. Healy,et al. The New Drug Approvals of 1996, 1997, and 1998: Drug Development Trends in the User Fee Era* , 2000 .
[4] J. DiMasi. New drug development in the United States from 1963 to 1999 , 2001, Clinical pharmacology and therapeutics.
[5] K. Haldar. Ducts, channels and transporters in Plasmodium-infected erythrocytes. , 1994, Parasitology today.
[6] I. Stephenson,et al. Drug treatment of tropical parasitic infections: recent achievements and developments. , 2000, Drugs.
[7] S. Hoffman,et al. Recent advances: Tropical medicine , 2000 .
[8] B. Pécoul,et al. Access to essential drugs in poor countries: a lost battle? , 1999, JAMA.
[9] L. Gilson,et al. Inequalities in health care use and expenditures: empirical data from eight developing countries and countries in transition. , 2000, Bulletin of the World Health Organization.
[10] P. Olliaro,et al. Drug development output from 1975 to 1996: what proportion for tropical diseases? , 1998, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.
[11] S. Berkley,et al. Initial lessons from public-private partnerships in drug and vaccine development. , 2001, Bulletin of the World Health Organization.
[12] G. Walt,et al. Global public-private partnerships: Part II--What are the health issues for global governance? , 2000, Bulletin of the World Health Organization.
[13] A. Clarke,et al. Creating the Costliest Orphan: The Orphan Drug Act in the Development of Ceredase™ , 1992, International Journal of Technology Assessment in Health Care.
[14] Henry G. Grabowski,et al. R&d Costs, Innovative Output and Firm Size in the Pharmaceutical Industry , 1995 .
[15] M. Kremer,et al. Perspectives on stimulating industrial research and development for neglected infectious diseases. , 2001, Bulletin of the World Health Organization.
[16] G. Walt,et al. Global public-private partnerships: Part I--A new development in health? , 2000, Bulletin of the World Health Organization.
[17] M. Kaddar. La mutation du marché mondial des vaccins , 1995 .
[18] Other. Human Development Report 2001: making new technologies work for human development , 2001 .
[19] Jürgen Drews,et al. Innovation deficit revisited: reflections on the productivity of pharmaceutical R&D , 1998 .
[20] C. Battistella,et al. Is orphan drug status beneficial to tropical disease control? Comparison of the American and future European orphan drug acts , 1999, Tropical medicine & international health : TM & IH.
[21] J. DiMasi,et al. Risks in new drug development: Approval success rates for investigational drugs , 2001, Clinical pharmacology and therapeutics.